Latest Commercialization News

Ten Sixty Four Limited’s latest quarterly report reveals a notable decline in gold output and cash reserves, alongside steady progress on key projects and a pivotal restructuring agreement.

Whitebark Energy has entered a definitive agreement to acquire King Energy, gaining access to one of Australia's largest prospective white hydrogen, helium, and hydrocarbon projects, while also resuming production at its Canadian oil field.

Mustera Property Group progresses design and marketing for its McCabe Street development while maintaining sales momentum at Forbes Residences, alongside a notable executive remuneration update.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.

Galan Lithium Limited advances its Hombre Muerto West project with a new mining permit and a significant resource upgrade at Candelas, positioning itself among the global lithium leaders and targeting production in H1 2026.

Hydrocarbon Dynamics secures a $165,000 repeat order from Dubai and closes a rights issue raising $808,582, while advancing multiple global trials of its HCD Multi-Flow product.

Pursuit Minerals has reported a remarkable 339% increase in lithium resources at its Rio Grande Sur project in Argentina, alongside plans to commence lithium carbonate production by Q1 2025. The company is also actively pursuing acquisitions and reviewing its gold assets amid tight cost controls.

Ovanti Limited has made significant strides in its plan to enter the US Buy Now Pay Later market, delivering a comprehensive strategic report and strengthening its executive team to support expansion.

Magnis Energy Technologies reports ongoing progress on its Nachu Graphite Project while grappling with Imperium3’s bankruptcy and a prolonged ASX trading suspension.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Larvotto Resources has reported robust progress at its Hillgrove Antimony-Gold Project, highlighted by exceptional drilling results and a successful $30 million capital raise, positioning the company for production by late 2025.